New Markers for Treatment Response to Radiotherapy in Prostate Cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- University of Basel
- Locations
- 1
- Primary Endpoint
- Bio-repository
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
The actual follow-up of patients undergoing definite radiotherapy for prostate cancer includes regular measurements of prostate specific antigen (PSA). Successful radiotherapy is critically dependent on local control of cancer; however, PSA takes 2-3 years to reach a nadir after therapy. We aim at collecting blood/urine after prostate massage before, and after radiotherapy in order to define new markers predicting local control earlier and more precisely than PSA.
Detailed Description
Patients will be closely followed for 5 years (weeks 0, 2, 4, 6, and months 2, 3, 6, 9, 12, 18, 24, and then yearly). Each assessment includes PSA measurement, urine collection after prostatic massage, and blood collection.
Investigators
Cyrill Rentsch
MD-PhD
University of Basel
Eligibility Criteria
Inclusion Criteria
- •All patients undergoing radiotherapy of biopsy confirmed clinically localised adenocarcinoma of the prostate
Exclusion Criteria
- •patients with inflammatory processes of the rectum
- •patients with no rectum due to previous surgery
Outcomes
Primary Outcomes
Bio-repository
Time Frame: first assessment using predifined markers after recruitment of 15 patients followed for 1 year